Last week, Coherus BioSciences, Inc. (“Coherus”) announced that the United States Food and Drug Administration (“FDA”) approved YUSIMRY™, an adalimumab biosimilar. YUSIMRY™ is a tumor necrosis factor blocker approved as a subcutaneous formulation. It is indicated for plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. This is
With a master’s degree in biotechnology by Johns Hopkins, and a bachelor of science from the University of Western Ontario with an honors double major in genetics and cell biology, Sheena Wang brings a background in both law and science to her role, integrating both in support of the firm’s IP practice and clients.